SCD and prostate adenocarcinoma: The results demonstrated elevated SCD expression in specific subgroups of PRAD patients, including those of Caucasian race (Figure 1C), those with a Gleason score of 8 (Figure 1D), those displaying the ERG-fusion molecular signature (Figure 1E), and those with N1 nodal metastasis status (Figure 1F).